Drug Database
SN

snake venom antibody-2 (ViperaTAb)

✓ Approved

MicroPharm · Polyclonal Antibodies · Polyclonal Antibodies

What is snake venom antibody-2?

snake venom antibody-2 is a polyclonal antibodies developed by MicroPharm. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesViperaTAb
CompanyMicroPharm
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

snake venom antibody-2 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Injury, poisoning and procedural complicationsVenom poisoning✓ Approved

Related Research Articles

PubMedFrontiers in chemistry2026-11-11

Mass spectrometry-based affinity capture of peptide ligands from complex venom mixtures.

Freuville Lou L, Fourmy Rudy R, Violette Aude A, Brans Alain A et al.

Animal venoms constitute a rich source of bioactive peptides targeting membrane receptors, including G protein-coupled receptors (GPCRs) and ligand-gated ion channels. However, identifying receptor-binding ligands directly from complex venom mixtures remains analytically challenging because venoms are highly diverse and conventional screening approaches have limited throughput. Here, we present a membrane-based affinity-capture workflow coupled to mass spectrometry to recover known receptor ligands and prioritize additional venom toxins for validation. The methodology combines native membrane preparations, label-free affinity capture, MALDI-TOF mass spectrometry, and LC-MS/MS-based proteomic identification within a single analytical workflow. Its performance was demonstrated using two pharmacologically distinct membrane receptor families: the human vasopressin type 2 receptor, a G protein-coupled receptor, and the muscle-type nicotinic acetylcholine receptor, a ligand-gated ion channel. The workflow recovered known ligands spanning endogenous peptides and disulfide-rich venom toxins and documented AVP-dependent changes in toxin recovery. Direct comparison of bound fractions obtained with nAChR-rich Torpedo membranes and control CHO membranes further identified toxins preferentially retained by each membrane preparation. By combining receptor-guided affinity selection with direct molecular identification, this strategy provides a versatile analytical platform for investigating ligand-receptor interactions and prioritizing bioactive peptides from highly complex natural mixtures. Beyond venom research, the approach is readily adaptable to other membrane receptors and molecular libraries for ligand discovery. Proteomic data are available via ProteomeXchange with identifier PXD084762.

PubMedThe Journal of experimental biology2026-11-11

An unusually complex venom system in araneophagous palp-footed spiders (Palpimanidae).

Michálek Ondřej O, Sentenská Lenka L, Walker Andrew A AA, Šedo Ondrej O et al.

Venoms are key adaptive traits in many animal lineages, yet their structural and functional diversity in spiders remains poorly investigated. Here, we present an initial characterization of the venom system of palp-footed spiders (Palpimanidae), a family specialized in hunting other spiders. Using micro-computed tomography, we found that the venom glands of the single species examined, Palpimanus gibbulus, exhibit a complex, multi-lobed morphology that is unusual among araneomorph spiders. Proteo-transcriptomic analyses of two Palpimanus venoms (P. gibbulus and P. cyprius) revealed highly diverse putative toxin repertoires comprising hundreds of peptides and proteins, including numerous novel putative neurotoxins, cytotoxins, enzymes, and allergens. Five major families of cysteine-rich palpitoxins were identified as the dominant putative neurotoxic components in both species, displaying conserved sequence motifs but distinct species-specific expression profiles. Our discovery of an unusual venom gland architecture in P. gibbulus and the diverse venom repertoires of the two araneophagic Palpimanus species broadens our understanding of the morphological and molecular diversity of spider venom systems.

PubMedMedicine2026-11-11

Efficacy and safety of herbal medicine for Hymenoptera stings: A systematic review and meta-analysis.

Kim Junseok J, Choi Dong-Jun DJ

Hymenoptera stings can cause severe anaphylaxis and venom-induced multiple organ dysfunction syndrome. Although conventional medicine (CM) can effectively control acute symptoms, its ability to prevent delayed venom-related organ injury remains limited. Therefore, herbal medicine (HM) combined with CM has been investigated to enhance venom detoxification and elimination. However, comprehensive evidence-based syntheses evaluating these interventions remain limited. We aimed to evaluate the efficacy and safety of HM + CM in mitigating venom-induced toxicity. A systematic review and meta-analysis of randomized controlled trials was conducted. Major electronic databases were searched for studies comparing HM + CM and CM alone. Outcomes included total effective rate and biomarkers of hepatic, renal, cardiac, and inflammatory responses. Overall, 11 randomized controlled trials involving 1443 patients were included. While the total effective rate was statistically higher in the HM + CM group than in the CM-alone group (risk ratio, 1.03), this represents a modest 3% relative improvement with limited clinical relevance for acute symptom control. Instead, adjunctive HM was significantly associated with lower levels of biomarkers of hepatic injury (aspartate aminotransferase, alanine aminotransferase, and total bilirubin), cardiac injury (creatine kinase and creatine kinase-myocardial band), systemic inflammation (C-reactive protein or high-sensitivity C-reactive protein), and renal dysfunction (serum creatinine), reflecting favorable changes in laboratory biomarkers associated with multi-organ toxicity. Although no adverse events were reported among the limited number of studies that formally assessed safety, the available evidence is insufficient to establish the definitive safety of HM. HM combined with conventional care appears to be a potentially useful adjunctive approach for Hymenoptera stings. While its additive effect on acute symptom resolution is clinically modest in the context of standard emergency care, adjunctive HM may offer a broader therapeutic scope. Specifically, it may complement clinical recovery while attenuating venom-induced systemic inflammation and improving related laboratory biomarkers.

PubMedAnalytical chemistry2026-11-11

One-step immunoassay for Interleukin-4 (IL4) Detection Using IL4-Receptor Mimotopes Screened from Fv-Antibody Library.

Kwon Soonil S, Jung Jaeyong J, Sung Jeong Soo JS, Bae Hyung Eun HE et al.

One-step immunoassay for IL4 was developed using a hypervariable part of immunoglobulin G (Fv-antibody) and switching-peptides. Conventional immunoassays require multistep procedures, whereas one-step immunoassays do not require additional steps. Fv-antibodies comprise three complementarity-determining regions (CDRs) and three frame regions (FRs). An Fv-antibody library was constructed using site-directed mutagenesis of the CDR3 region (with 11 amino acid residues) and expressed on the outer membrane of Escherichia coliusing autodisplay technology. Two IL4 receptor (IL4r) mimotopes, designated Fv-1 and Fv-2, were screened from the Fv-antibody library using the anti-IL4r antibody. These mimotopes were expressed as soluble proteins with three CDRs and four FRs. Using the surface plasmon resonance (SPR) biosensor, the binding affinities of the mimotopes Fv-1 and Fv-2 to the anti-IL4r antibody were 39.5 and 48.8 nM, respectively. Using HEK-Blue IL4 cells, the expressed IL4r mimotopes were analyzed to determine whether they compete with IL4r for the binding of IL4. The inhibition constants of mimotopes were 2.3 and 1.9 μM for Fv-1 and Fv-2, respectively. The interaction between mimotopes and IL4r (binding affinity and amino acids) was analyzed and compared with that of IL4 using a docking simulation. The interaction between mimotopes and IL4 occurred at binding sites on IL4r. A complex of expressed mimotopes and switching-peptides (fluorescence-labeled) was used for detecting IL4. The binding of IL4 to the complex resulted in the quantitative release of switching-peptides. IL4 detection was within the clinically required IL4 concentration range.

PubMedZhonghua yi xue za zhi2026-11-11

[Analysis of registry data on unexpected red blood cell antibodies in Chaoyang district, Beijing, 2024 to 2025].

Cai J J, Lu H K HK, Wang D G DG, Zhang K Y KY et al.

To analyze the registry data on unexpected red blood cell antibodies in chaoyang district, Beijing and investigate the clinical application value of the regional red blood cell unexpected antibody registration system. A retrospective analysis was conducted on the clinical data and antibody specificity of patients with positive antibody screening registered in this system from 2024 to 2025. The comparison between the two groups was conducted using independent sample t-test, Mann-Whitney U test, χ2 test or Fisher's exact probability method. The results showed that a total of 887 patients with positive antibody screening results were registered, including 288 males and 599 females. Statistically significant differences were observed between male and female patients in terms of age, RhD blood group, and transfusion history (P<0.05). Unexpected antibodies were identified in 827 cases, including 798 cases of alloantibodies. The three most frequently detected blood group systems were Rh system [37.47% (299/798)], MNS system[35.09% (280/798)], and Lewis system [13.28% (106/798)]. The five most frequent antibodies were anti-E [28.82% (230/798)], anti-M [26.69% (213/798)], anti-Lea [11.53% (92/798)], anti-Mia [7.52% (60/798)] and anti-Fyb [4.64% (37/798)]. There were 704 patients with a single unexpected antibody and 123 patients with multiple unexpected antibodies. Statistically significant differences were found in age and transfusion history between the two groups (P<0.05). Among registered pregnant patients, t alloantibodies were predominantly anti-M, anti-E, and anti-Lea. 38 patients had multiple positive antibody screening records, with 4 cases transitioning from single to multiple antibodies. Of the 11 patients who visited multiple institutions, 2 experienced a similar progression. The above results indicate that the regional red blood cell unexpected antibody registration system can reveal antibody distribution characteristics, identify the risk of fragmented records due to cross-institutional healthcare visits, and provide a feasible pathway for improving regional transfusion safety and conserving blood resources.

PubMedViral immunology2026-11-11

peleke-1: A Suite of Protein Language Models Fine-Tuned for Targeted Antibody Sequence Generation.

Santolla Nicholas N, Pridgen Trey T, Nigam Prbhuv P, Ford Colby T CT

The discovery of therapeutic antibodies is a traditionally arduous process. Today, the lab-based process of antibody discovery consists of several time-consuming steps that involve live animal immunization, B-cell harvesting, hybridoma creation, and then downstream engineering and evaluation. However, the use of artificial intelligence in drug design has previously been shown effective in the rapid generation of protein-specific binders, small molecules, and even antibody therapeutics, thereby replacing some of the primary steps of the drug discovery process. Here, we present peleke-1, a suite of protein language models fine-tuned from state-of-the-art large language models using curated antibody-antigen complex data. These models generate targeted antibody Fv sequences for a given antigen sequence input at-scale. This suite of models provides a reliable, artificial intelligence-driven approach for in silico therapeutic antibody discovery along with an open-source framework for future antibody language model tuning.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about snake venom antibody-2